Overview

Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied by nocturia.
Phase:
Phase 4
Details
Lead Sponsor:
JW Pharmaceutical
Treatments:
Silodosin